Introduction: Brotowali (Tinospora crispa) has been traditionally used as an antidiabetic drug. DPP-IV inhibitor as an antidiabetic will increase insulin secretion. It indirectly escalates incretin hormones, such as Glucagon-Like peptide-1 (GLP-1) which depends on glucose. This study predicts potential compounds from the Brotowali plants, such as DPP-IV inhibitors, using the Molegro Virtual Docker (MVD). Materials and methods: Before the molecular docking simulation, internal validation and external validation are necessary. Internal validation was carried out by re-docking the native ligands in the DPP-IV enzyme crystal structure (PDB codes 3G0B, 3W2T, and 3BJM). The external validation was carried out by simultaneous docking of 59 active compounds and 1918 inactive compounds (decoys) from the A Directory of Useful Decoys (DUD) database with PDB code 3G0B on 16 combinations, four search algorithms, and four functions scoring. Results and discussion: The molecular docking simulation was carried out on 50 compounds from the Brotowali plant and alogliptin as standard compounds with PDB code 3G0B. The best results of the docking method validation yielded the RMSD values of 0.43 and EF1% of 20.34 and EF20% of 3.1 (the combination of search algorithm Moldock optimizer and scoring function Moldock score). The re-rank score of 5 compounds from the Brotowali plant (Rumphioside C, Borapetoside E, Borapetoside F, Rumphioside I, and 6’-O-Lactoyl Borapetoside B) were -107.7 kcal/mol; -105.4 kcal/mol; -104.2 kcal/mol, and -102.8 kcal/mol. Alogliptin (standard ligands) had a re-rank score of -101.6 kcal/mol. The combination of search algorithms MolDock optimizer and scoring function MolDock score is a valid protocol with a good result. The similarity of the binding sites of Borapetoside E and 6’-O-Lactoyl Borapetoside B is 75% when compared to the alogliptin binding sites (Glu 205, Glu 206, Tyr 547). Conclusion: Based on the re-rank score and binding sites similarity, Borapetoside E and 6’-O-Lactoyl Borapetoside B have potential as an antidiabetic drug with a mechanism of action of DPP-IV inhibitors.
Objective: This study aims to identify potential compounds as inhibitors of DPP-4 from Tinospora crispa. Material and Method: Tinospora crispa stem powder was extracted by ultrasonication. The DPP-4 inhibition test used the MAK 203 screening kit protocol. LC-MS/MS was used to determine the chemical profile. MetaboAnalyst5 and SIMCA were used to analyze the dataset. Molecular docking was performed using Molegro virtual docker, and molecular dynamics simulations were performed using YASARA dynamics employing the AMBER14 force field. Result and Discussion: The percentage inhibition of DPP-4 results showed that the most active was 96% ethanol extract. Orthogonal projection to latent structure (OPLS) analysis provides that 6'-O-LactoylBorapetoside B correlates most with DPP-4 inhibitory activity based on VIP value and Y coefficient. In the docking molecular analysis, 6’-O-LactoylBorapetoside B was predicted to be active as DPP-4 inhibitors with a lower rerank score (−106.51 Kcal/Mol) than alogliptin as a reference (−96.02 Kcal/mol). In molecular dynamics simulation for 100 ns, 6’-O-LactoylBorapetoside B complex of binding with DPP-4 protein was stable with the movement of the RMSD value below 3Å. 6'-O-Lactoyl Borapetoside B has a potential of being a DPP-4-inhibitor. But these results must be tested in vitro and in vivo in order to confirm its activity as a DPP-4 inhibitor.